section name header

Pronunciation

a-mee-noe-ka-PRO-ik A-sid

Classifications

Therapeutic Classification: hemostatic agents

Pharmacologic Classification: fibrinolysis inhibitors

Indications

REMS


Unlabeled Use:
  • Prevention of recurrent subarachnoid hemorrhage.
  • Prevention of bleeding following oral surgery in hemophiliacs.
  • Management of severe hemorrhage caused by thrombolytic agents.

Action

  • Inhibits activation of plasminogen.
Therapeutic effects:
  • Inhibition of fibrinolysis.
  • Stabilization of clot formation.

Pharmacokinetics

Absorption: Rapidly absorbed following oral administration.

Distribution: Widely distributed to tissues.

Metabolism/Excretion: Mostly eliminated unchanged by the kidneys.

Half-Life: Unknown.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown2 hrN/A
IVunknown2 hrN/A



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: arrhythmias, hypotension (IV only)

EENT: nasal stuffiness, tinnitus

GI: anorexia, bloating, cramping, diarrhea, nausea

GU: diuresis, renal failure

MS: myopathy

Neuro: dizziness, malaise

Interactions

Drug-drug:

Route/Dosage

Acute Bleeding Syndromes due to Elevated Fibrinolytic Activity

Subarachnoid Hemorrhage

Prevention of Bleeding Following Oral Surgery in Hemophiliacs

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

IV Administration:

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Amicar

Code

NDC Code